These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37904317)

  • 1. What is the role of risedronate in the primary and secondary prevention of fractures associated with osteoporosis in postmenopausal women? A Cochrane review summary with commentary.
    Arman S
    Int J Rheum Dis; 2024 Jan; 27(1):e14940. PubMed ID: 37904317
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of osteoporosis-related fractures among postmenopausal women and older men.
    Rahmani P; Morin S
    CMAJ; 2009 Nov; 181(11):815-20. PubMed ID: 19841053
    [No Abstract]   [Full Text] [Related]  

  • 3. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells G; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
    Cochrane Database Syst Rev; 2008 Jan; (1):CD004523. PubMed ID: 18254053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
    Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.
    Gu JM; Wang L; Lin H; Chen DC; Tang H; Jin XL; Xia WB; Hu YQ; Fu WZ; He JW; Zhang H; Wang C; Yue H; Hu WW; Liu YJ; Zhang ZL
    Acta Pharmacol Sin; 2015 Jul; 36(7):841-6. PubMed ID: 26051110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
    Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Rackoff P
    Clin Interv Aging; 2009; 4():207-14. PubMed ID: 19503783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
    Bobba R; Adachi JD
    Clin Interv Aging; 2007; 2(3):275-82. PubMed ID: 18044178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J; Takeda T; Sato Y
    Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary prevention of osteoporotic fractures: why not apply the evidence?
    Ferrari S
    Swiss Med Wkly; 2008 Nov; 138(45-46):656-7. PubMed ID: 19043812
    [No Abstract]   [Full Text] [Related]  

  • 16. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study.
    Eisman J; Clapham S; Kehoe L;
    J Bone Miner Res; 2004 Dec; 19(12):1969-75. PubMed ID: 15537439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmenopausal osteoporosis: another approach to management.
    Cole R
    J Fam Pract; 2010 Jun; 59(6):E1-7. PubMed ID: 20544058
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
    Waltman N; Kupzyk KA; Flores LE; Mack LR; Lappe JM; Bilek LD
    Osteoporos Int; 2022 Feb; 33(2):475-486. PubMed ID: 34519832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A; Adachi JD; Guyatt G; Papaioannou A; Robinson VA; Shea BJ; Tugwell P; Waldegger LM; Weaver B; Wells G; Zytaruk N
    Cochrane Database Syst Rev; 2007 Jul; (1):CD004523. PubMed ID: 17636764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
    Poole KE; Warburton EA; Reeve J
    Neurology; 2005 Nov; 65(9):1513-4; author reply 1513-4. PubMed ID: 16275859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.